Seralutinib shows potential benefit in high-risk pulmonary arterial hypertension subgroups; safety data note cough and liver enzyme elevations as risks.
Myosteatosis on computed tomography as a predictor of therapeutic response to CDK4/6 inhibitors plus aromatase inhibitors in patients with advanced breast cancer. Subgroup OS HR (95% CI) OS p-value ...
Subgroup analysis in clinical trials constitutes a vital methodological tool to uncover differential treatment effects within specified categories of patients. This approach enables researchers to ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results